Clinical correlates of serum 25-hydroxyvitamin D in Parkinson's disease
Barichella M, Cereda E, Iorio L, Pinelli G, Ferri V, Cassani E, Bolliri C, Caronni S, Pusani C, Schiaffino MG, Giana A, Quacci E, Esposito C, Monti Guarnieri F, Colombo A, Sorbo FD, Cilia R, Sacilotto G, Riboldazzi G, Zecchinelli AL, Pezzoli G
Nutritional neuroscience · 11 citations
How it was studied
- Design
- Cross-sectional study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Nonprofit
- Fondazione Grigioni per il Morbo di Parkinson
- Nonprofit
- Brain and Malnutrition in Chronic Disease Association Onlus
Based on 2 listed funder(s).
Publication
- Published
- 2020-11-05 · Nutr Neurosci · vol. 25 · issue 6 · pp. 1128–1136
- Publisher
- Taylor & Francis
- Cited
- 24 citations · more than 84% of similar papers · 1.6× the field average
- References
- 45 works
- Access
- Paywalled
- Research areas
- Vitamin D Research Studies · Parkinson's Disease Mechanisms and Treatments · Biotin and Related Studies
- Keywords
- Vitamin D and neurology, Internal medicine, Medicine, Parkinson's disease, vitamin D deficiency, Gastroenterology, Population, Disease, Rating scale, Dopaminergic, Psychology, Dopamine
- MeSH
- humans, parkinson disease, calcifediol, vitamin d, cross-sectional studies
21 authors
From IT
- Michela BarichellaIstituto Ortopedico Gaetano Pini; Grigioni Foundation for Parkinson's disease
- Emanuele Cereda · correspondingPoliclinico San Matteo Fondazione; Istituti di Ricovero e Cura a Carattere Scientifico
- Laura Iorio
- Giovanna PinelliIstituto Ortopedico Gaetano Pini; Grigioni Foundation for Parkinson's disease
- Valentina FerriIstituto Ortopedico Gaetano Pini; Grigioni Foundation for Parkinson's disease
- Erica CassaniGrigioni Foundation for Parkinson's disease
Abstract
Background
Parkinson's disease (PD) patients have lower levels of serum 25-hydroxyvitamin D (25(OH)D) than the general population. Previous studies have suggested a negative association between 25(OH)D and clinical features of PD, but the data are inconsistent.
Materials and methods
We conducted a cross-sectional, observational study. Serum 25(OH)D, disease (Hoehn-Yahr stage [HY]) and clinical symptom (Unified Parkinson Disease Rating Scale [UPDRS]) severity and global cognitive functions (Mini-Mental State Examination [MMSE]) were studied in 500 consecutive PD patients not using vitamin D supplements. Information on sunlight exposure and dietary intakes (using a 66-item food frequency questionnaire) were also collected. A convenient sample of age and sex-matched community healthy controls (N = 100) was included as a control group.
Results
PD patients had lower 25(OH)D serum levels than controls. Deficiency status (P = .002) and vitamin D intake (P = .009). In multivariate models, using a Mendelian randomization approach, lower serum 25(OH)D was associated with more severe disease (HY, P = .035), worse clinical symptoms (UPDRS Part-III total score [P = .006] and dopaminergic [P = .033] and non-dopaminergic subscores [P = .001]) and greater global cognitive function impairment (P = .041). Neither cognitive functions nor clinical features were associated with reduced intake of vitamin D and sunlight exposure.
Conclusion
: Serum 25(OH)D was negatively correlated with disease and symptoms severity, as well as with global cognitive functions. Our study adds to the evidence that low 25(OH)D may affect the progression of PD negatively. Intervention studies in this area are required.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.